Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.65 |
| ▸ | CLK3 | P49761 | 7/20 | 0.65 |
| ▸ | CLK2 | P49760 | 6/20 | 0.65 |
| ▸ | WNT1 | P04628 | 2/20 | 0.56 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510153 | 0.85 | MKNK1 (0.67) | DYRK1ACLK3CLK2LRRK2MKNK1 | |
| SCHEMBL758691 | 0.84 | AKT1 (0.52) | DYRK1ACLK3CLK2WNT1MAP2K4 | |
| SCHEMBL5514698 | 0.83 | MKNK1 (0.72) | DYRK1ACLK3CLK2WNT1MAP2K4 | |
| SCHEMBL18446560 | 0.79 | CLK3 (0.82) | DYRK1ACLK3CLK2WNT1IDO1 | |
| SCHEMBL18482640 | 0.79 | CLK3 (0.82) | DYRK1ACLK3CLK2WNT1MAP2K4 | |
| SCHEMBL18485128 | 0.79 | CLK3 (1.00) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL18487462 | 0.78 | DYRK1A (0.69) | DYRK1ACLK3CLK2WNT1MAP2K4 | |
| SCHEMBL18441945 | 0.78 | DYRK1A (0.78) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL20455095 | 0.78 | DYRK1A (0.82) | DYRK1ACLK3CLK2WNT1MAP2K4 | |
| SCHEMBL10213963 | 0.77 | JAK2 (0.69) | DYRK1ACLK3CLK2WNT1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| CN-101437519-A | Indazole compounds | ABBOTT LAB (US) | 2009-05-20 | — | — | CN | disclosed |
| EP-2001480-A2 | INDAZOLE COMPOUNDS | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | DYRK1A 3722/4885CLK3 1887/4885CLK2 2684/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | DYRK1A 3722/4885CLK3 1887/4885CLK2 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.